| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
7,710,000 |
| Market
Cap: |
3.08(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.352 - $3.11 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Trevena is a biopharmaceutical company. Co.'s primary product, OLINVYK™ (oliceridine) injection, is an opioid agonist for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Co.'s product candidates include: TRV027, which is an angiotensin II type 1 receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, which is a G-protein biased delta-opioid receptor agonist as a compound with a mechanism for the treatment of acute migraine; and TRV045, which is a S1P modulator.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
31,785 |
| Total Sell Value |
$0 |
$0 |
$0 |
$13,032 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bourdow Carrie L. |
President & CEO |
• • – |
2020-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
471,100 |
1,264,060 |
|
- |
|
| Demitrack Mark |
Sr. VP & Chief Medical Officer |
• – – |
2020-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
172,700 |
444,181 |
|
- |
|
| Yoder Robert T |
SVP, Chief Commercial Officer |
• – – |
2020-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
141,300 |
357,866 |
|
- |
|
| Bourdow Carrie L. |
President & CEO |
• • – |
2020-12-07 |
4/A |
D |
$2.27 |
$344,323 |
D/D |
(151,684) |
1,245,310 |
|
- |
|
| Bourdow Carrie L. |
President & CEO |
• • – |
2020-12-07 |
4 |
D |
$2.27 |
$301,760 |
D/D |
(132,934) |
792,960 |
|
- |
|
| Yoder Robert T |
Sr VP Chief Commercial Officer |
• – – |
2020-12-07 |
4 |
D |
$2.27 |
$83,282 |
D/D |
(36,688) |
216,566 |
|
- |
|
| Demitrack Mark |
Sr. VP & Chief Medical Officer |
• – – |
2020-12-07 |
4 |
D |
$2.27 |
$110,224 |
D/D |
(48,557) |
271,481 |
|
- |
|
| Shin Barry |
Chief Financial Officer |
• – – |
2020-12-07 |
4 |
D |
$2.27 |
$95,024 |
D/D |
(41,861) |
403,600 |
|
- |
|
| Shin Barry |
Chief Financial Officer |
• – – |
2020-06-25 |
4 |
D |
$1.72 |
$40,487 |
D/D |
(23,539) |
445,461 |
|
- |
|
| Applebaum Scott |
CLCO; SVP Regulatory Affairs |
• – – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
250,000 |
|
- |
|
| Demitrack Mark |
Sr. VP & Chief Medical Officer |
• – – |
2019-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
213,000 |
320,038 |
|
- |
|
| Shin Barry |
Chief Financial Officer |
• – – |
2019-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
194,000 |
469,000 |
|
- |
|
| Bourdow Carrie L. |
President and CEO |
• • – |
2019-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
657,000 |
925,894 |
|
- |
|
| Yoder Robert T |
Sr. VP, Chief Business Officer |
• – – |
2019-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
167,000 |
253,254 |
|
- |
|
| Yoder Robert T |
Sr. VP, Chief Business Officer |
• – – |
2019-12-02 |
4 |
D |
$0.69 |
$4,735 |
D/D |
(6,874) |
86,254 |
|
- |
|
| Bourdow Carrie L. |
President and CEO |
• • – |
2019-12-02 |
4 |
D |
$0.69 |
$12,265 |
D/D |
(17,804) |
268,894 |
|
- |
|
| Demitrack Mark |
Sr. VP & Chief Medical Officer |
• – – |
2019-12-02 |
4 |
D |
$0.69 |
$6,188 |
D/D |
(8,982) |
107,038 |
|
- |
|
| Shin Barry |
Chief Financial Officer |
• – – |
2019-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
275,000 |
275,000 |
|
- |
|
| Bourdow Carrie L. |
President and CEO |
• • – |
2019-06-03 |
4 |
D |
$1.17 |
$20,828 |
D/D |
(17,802) |
286,698 |
|
- |
|
| Hamill John P. |
VP Fin,Princ Fin&Acct Officer |
• – – |
2019-06-03 |
4 |
D |
$1.17 |
$6,454 |
D/D |
(5,516) |
82,234 |
|
- |
|
| Demitrack Mark |
Sr VP & Chief Medical Officer |
• – – |
2019-06-03 |
4 |
D |
$1.17 |
$10,507 |
D/D |
(8,980) |
116,020 |
|
- |
|
| Yoder Robert T |
Sr. VP, Chief Business Officer |
• – – |
2019-06-03 |
4 |
D |
$1.17 |
$8,040 |
D/D |
(6,872) |
93,128 |
|
- |
|
| Hamill John P. |
VP Fin,Princ Fin&Acct Officer |
• – – |
2019-05-31 |
4 |
B |
$1.16 |
$8,700 |
D/D |
7,500 |
87,750 |
2.74 |
- |
|
| Gowen Maxine |
President & CEO |
• • – |
2019-02-01 |
4 |
B |
$1.02 |
$51,000 |
D/D |
50,000 |
54,000 |
2.81 |
- |
|
| Bourdow Carrie L. |
President and CEO |
• • – |
2019-02-01 |
4 |
A |
$1.02 |
$51,000 |
D/D |
50,000 |
304,500 |
|
- |
|
142 Records found
|
|
Page 3 of 6 |
|
|
